Literature DB >> 1567898

Inhibition of transplasma membrane electron transport by transferrin-adriamycin conjugates.

I L Sun1, E E Sun, F L Crane, D J Morré, W P Faulk.   

Abstract

Transplasma membrane electron transport from HeLa cells, measured by reduction of ferricyanide or diferric transferrin in the presence of bathophenanthroline disulfonate, is inhibited by low concentrations of adriamycin and adriamycin conjugated to diferric transferrin. Inhibition with the conjugate is observed at one-tenth the concentration required for adriamycin inhibition. The inhibitory action of the conjugate appears to be at the plasma membrane since (a) the conjugate does not transfer adriamycin to the nucleus, (b) the inhibition is observed within three minutes of addition to cells, and (c) the inhibition is observed with NADH dehydrogenase and oxidase activities of isolated plasma membranes. Cytostatic effects of the compounds on HeLa cells show the same concentration dependence as for enzyme inhibition. The adriamycin-ferric transferrin conjugate provides a more effective tool for inhibition of the plasma membrane electron transport than is given by the free drug.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1567898     DOI: 10.1016/0005-2736(92)90165-i

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  4 in total

1.  Is the drug-responsive NADH oxidase of the cancer cell plasma membrane a molecular target for adriamycin?

Authors:  D J Morré; C Kim; M Paulik; D M Morré; W P Faulk
Journal:  J Bioenerg Biomembr       Date:  1997-06       Impact factor: 2.945

Review 2.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer.

Authors:  Tracy R Daniels; Ezequiel Bernabeu; José A Rodríguez; Shabnum Patel; Maggie Kozman; Diego A Chiappetta; Eggehard Holler; Julia Y Ljubimova; Gustavo Helguera; Manuel L Penichet
Journal:  Biochim Biophys Acta       Date:  2011-08-05

Review 3.  Transferrin receptor-mediated endocytosis: a useful target for cancer therapy.

Authors:  Stephanie Tortorella; Tom C Karagiannis
Journal:  J Membr Biol       Date:  2014-02-27       Impact factor: 1.843

4.  Doxorubicin-transferrin conjugate selectively overcomes multidrug resistance in leukaemia cells.

Authors:  Dorota Łubgan; Zofia Jóźwiak; Gerhard G Grabenbauer; Luitpold V R Distel
Journal:  Cell Mol Biol Lett       Date:  2008-10-10       Impact factor: 5.787

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.